Table 3.

Comparison of D₁ to D₂ Lymphadenectomy in meta-analyses regarding oncologic outcome.

	First author (reference)	Included trials	OS D2 vs D1	CI	p	I2	p(I2)
OS	Mocellin (25, 26)*	H, B, T, D, I	HR: 0.91	0.71–1.17	0.47	64%	0.024
	Mocellin (26)	H, T	HR: 0.63	0.40–0.99	0.047	76%	0.039
	Mocellin (26) *	B,D,I	HR: 0.98	0.86–1.12	0.8	0%	0.81
	El-Sedfy (27)	B, T, D, I	OR: 1.11	0.84–1.47	0.47	45%	0.14
	Jiang (28),*	H, B, T, D, I	RR: 0.98	0.88–1.09	0.74	0%	0.78
	El-Sedfy (27) 5 year pT1	B, T, D, I	OR: 0.60	0.23–1.57	0.29	58%	0.09
	El-Sedfy (27) 5 year pT2		OR: 1.05,	0.67–1.64	0.83	31%	0.24
	El-Sedfy (27) 5 year pT3		OR: 1.64	1.01–2.67	0.05	0%	0.94
	El-Sedfy (27) 5 year pN+		OR: 1.36,	0.98–1.87	0.06	0%	0.45
	El-Sedfy (27) 5yr N0		OR: 0.77	0.49–1.22	0.26	23%	0.26
DSS	Mocellin (25, 26)*	B, T, D, I	HR: 0.81	0.71–0.92	0.002	40%	0.17
DFS	Mocellin (26)*	B, T, D,	HR: 0.95	0.84–1.07	0.37	36%	0.21
GCRD	Jiang (28) *	B, T, D,	RR: 1,19	0.98–1.44	0.07	55%	0.11
	Jiang (28) *	T, D,	RR: 1,31	0.12–1.52	<0.001	0%	0.76

^*Duration of follow up varies in the included studies.

OS, Overall survival; DFS, disease free survival; DSS, disease specific survival; GCRD, gastric cancer related death.

CI, 95% CI; HR, Hazard ratio; OR, Odd ratio; RR, relative risk; 5 year, 5 year follow up.

H, Hong Kong; B, British; T, Taiwanese; D, Dutch; I, Italian study.